Castle Biosciences (CSTL) Cash from Investing Activities (2018 - 2026)

Castle Biosciences has disclosed Cash from Investing Activities across 9 years of filings, most recently posting -$25.8 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$25.8 million, down 15.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$63.7 million (down 20.56% YoY), and the FY2025 annual result was -$60.4 million, down 20.4% from the prior year.
• Cash from Investing Activities came in at -$25.8 million for Q1 2026 at Castle Biosciences, down from $8.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $16.6 million in Q1 2023 to a low of -$134.2 million in Q3 2022.
• The 5-year median for Cash from Investing Activities is -$15.4 million (2023), against an average of -$18.8 million.
• Across the five-year window, Cash from Investing Activities sank 14434.13% in 2022 and jumped 4225.37% in 2023, its largest moves.
• Castle Biosciences' Cash from Investing Activities stood at -$4.5 million in 2022, then slumped by 71.17% to -$7.7 million in 2023, then jumped by 175.21% to $5.8 million in 2024, then surged by 53.05% to $8.8 million in 2025, then sank by 392.19% to -$25.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$25.8 million (Q1 2026), $8.8 million (Q4 2025), and -$18.4 million (Q3 2025), per Business Quant data.